denali
therapeutics
highlight
progress
across
broad
biotherapeutics
portfolio
neurodegeneration
enabled
barrier
bbb
tv
platform
virtual
r
day
today
proprietary
differentiated
transport
vehicle
tv
technology
shows
potential
solve
bbb
challenge
delivering
biotherapeutics
brain
new
preclinical
data
support
potential
systemic
administration
etv
ids
treat
neurological
pathology
hunter
syndrome
replace
therapy
early
safety
biomarker
data
ongoing
phase
trial
expected
year
end
positive
data
would
validate
denali
tv
technology
brain
delivery
broad
biotherapeutic
portfolio
enabled
tv
technology
includes
enzymes
antibodies
oligonucleotides
across
multiple
therapeutic
areas
including
neurodegenerative
diseases
lysosomal
storage
disorders
oncology
south
san
francisco
globe
newswire
denali
therapeutics
nasdaq
dnli
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
neurodegenerative
diseases
host
virtual
r
day
webinar
today
highlighting
progress
across
company
broad
diverse
biotherapeutics
portfolio
enabled
bbb
transport
vehicle
tv
platform
webinar
begin
eastern
time
accessed
delivering
biotherapeutics
brain
historically
significant
challenge
field
hindering
efforts
develop
medicines
neurodegenerative
diseases
said
ryan
watts
denali
chief
executive
officer
addressing
challenge
core
scientific
principle
strategy
defeat
degeneration
designed
tv
technology
access
brain
biotherapeutics
addition
small
molecule
therapeutic
programs
believe
biotherapeutics
portfolio
potential
yield
effective
new
medicines
pleased
share
recent
progress
portfolio
biotherapeutic
programs
said
carole
ho
denali
chief
medical
officer
especially
excited
highlight
new
preclinical
data
enzyme
transport
vehicle
iduronate
etv
ids
program
supports
potential
replace
therapy
address
current
unmet
patient
need
hunter
syndrome
mps
ii
track
announce
early
biomarker
data
ongoing
phase
study
etv
ids
hunter
syndrome
year
end
positive
data
would
provide
biomarker
tv
technology
hunter
patients
unlock
large
platform
potential
neurodegeneration
therapeutic
r
day
highlights
related
biotherapeutic
programs
denali
tv
technology
engineered
significantly
increase
brain
access
multiple
therapeutic
modalities
enzyme
protein
replacement
therapy
via
etv
ptv
antibody
delivery
via
atv
oligonucleotide
delivery
via
otv
enhancing
unlocking
brain
targets
biotherapeutics
company
share
new
preclinical
data
select
biotherapeutic
programs
portfolio
including
enzyme
tv
etv
protein
tv
ptv
platform
etv
ids
robustly
modulated
biomarkers
including
glycosaminoglycans
gags
lysosomal
lipid
biomarkers
neurofilament
light
associated
improvements
neurobehavioral
deficits
motor
function
well
correction
skeletal
disease
manifestations
systemic
administration
mouse
model
hunter
syndrome
etv
sgsh
significantly
reduced
levels
gags
brain
cerebral
spinal
fluid
csf
following
single
dose
mouse
model
sanfilippo
syndrome
type
mps
iiia
ptv
progranulin
ptv
pgrn
restored
lysosomal
function
reduced
microglial
activation
brain
granulin
mice
bmp
identified
translatable
biomarker
frontotemporal
dementia
humans
antibody
tv
atv
platform
atv
abeta
higher
brain
uptake
improved
engagement
plaques
compared
abeta
antibody
similar
doses
mouse
model
alzheimer
disease
atv
showed
enhanced
brain
uptake
greater
impact
microglia
similar
doses
exposure
standard
antibody
mice
atv
showed
increased
brain
concentrations
improved
activity
mouse
xenograft
model
suggesting
potential
treatment
central
nervous
system
cns
metastases
oligonucleotide
tv
otv
platform
antisense
otv
knocked
target
gene
expression
brain
spinal
cord
systemic
administration
via
intravenous
infusion
standard
antisense
oligonucleotide
aso
control
effect
denali
secarna
pharmaceuticals
gmbh
kg
leader
aso
technology
recently
entered
research
option
agreement
develop
novel
aso
molecules
delivered
cns
using
denali
otv
technology
r
day
summary
etv
ids
flagship
program
denali
flagship
etv
program
etv
ids
hunter
syndrome
mps
ii
rare
neurodegenerative
lysosomal
storage
disorder
caused
mutation
gene
encodes
enzyme
ids
existing
enzyme
replacement
therapies
erts
effectively
cross
bbb
address
neurodegeneration
patients
intravenous
administration
etv
ids
designed
take
advantage
highly
vascularized
cns
nearly
miles
capillaries
human
brain
actively
transport
biotherapeutics
receptor
mediated
transcytosis
brain
denali
engineered
aspects
tv
technology
accessing
brain
regions
brain
cell
types
enable
enhance
therapeutic
benefit
intravenous
administration
denali
investigational
etv
ids
aims
treat
behavioral
cognitive
aspects
hunter
syndrome
maintaining
benefit
entire
body
previously
denali
published
research
showing
first
time
patients
hunter
syndrome
abnormalities
gags
substrate
ids
enzymatic
activity
correlated
biomarkers
secondary
lysosomal
dysfunction
gangliosides
bmp
glucer
axonal
injury
company
share
published
new
biomarker
data
multiple
studies
mouse
model
hunter
syndrome
demonstrating
systemically
administered
etv
ids
achieved
high
concentration
broad
distribution
ids
enzymes
brain
led
reduction
gags
corrected
abnormal
accumulation
lysosomal
lipids
gangliosides
bmp
glucer
slowed
neuroaxonal
injury
evidenced
reduction
addition
new
preclinical
data
presented
showing
systemic
administration
etv
ids
associated
improvements
neurobehavioral
deficits
spatial
learning
memory
deficits
motor
function
locomotor
performance
agility
well
correction
skeletal
disease
manifestations
abnormal
increased
trabecular
cortical
bone
mass
femur
denali
also
share
additional
details
status
design
ongoing
phase
trial
began
enrolling
pediatric
patients
hunter
syndrome
august
denali
expects
announce
data
interim
analysis
safety
biomarker
data
csf
gag
reduction
year
end
based
preclinical
data
showing
gag
reduction
csf
correlates
gag
reduction
brain
systemic
administration
etv
ids
denali
considers
reduction
csf
gag
levels
approximately
percent
patients
tv
technology
furthermore
approximate
percent
reduction
csf
gag
levels
anticipated
associated
subsequent
improvements
lysosomal
function
neurodegeneration
biomarkers
additional
biomarkers
lysosomal
function
neuroaxonal
injury
measured
ongoing
phase
trial
company
expects
additional
safety
biomarker
data
phase
trial
available
phase
trial
designed
inform
dose
selection
evaluate
effects
treatment
neurocognitive
outcomes
potential
subsequent
phase
pivotal
trial
virtual
r
day
webinar
agenda
following
topics
speakers
featured
denali
virtual
r
day
webinar
times
eastern
time
introduction
barrier
transport
vehicle
tv
ryan
chief
executive
officer
hunter
syndrome
simon
jones
mrcpch
mbchb
consultant
paediatric
inborn
errors
metabolism
willink
unit
manchester
centre
genomic
medicine
saint
mary
hospital
medical
director
nihr
manchester
children
clinical
research
facility
honorary
senior
lecturer
university
manchester
tv
flagship
program
etv
ids
carole
ho
chief
medical
head
development
q
session
break
tv
portfolio
joe
chief
scientific
officer
unlocking
tv
platform
alex
chief
operating
officer
q
session
virtual
r
day
webinar
information
live
webinar
begin
eastern
time
conclude
approximately
eastern
time
registration
accessible
investor
page
denali
website
following
webinar
replay
available
limited
time
denali
website
denali
tv
platform
bbb
essential
maintaining
brain
microenvironment
protecting
harmful
substances
pathogens
circulating
bloodstream
historically
bbb
posed
significant
challenges
drug
development
cns
diseases
preventing
drugs
reaching
brain
therapeutically
relevant
concentrations
denali
tv
platform
proprietary
technology
designed
effectively
deliver
large
therapeutic
molecules
antibodies
enzymes
proteins
oligonucleotides
across
bbb
intravenous
administration
tv
technology
based
engineered
fc
fragments
bind
specific
natural
transport
receptors
expressed
bbb
delivered
brain
receptor
mediated
transcytosis
denali
research
shown
animal
models
antibodies
enzymes
engineered
tv
technology
demonstrated
greater
brain
exposure
similar
antibodies
enzymes
without
technology
improved
exposure
broad
distribution
brain
may
increase
therapeutic
efficacy
enabling
widespread
achievement
therapeutically
relevant
concentrations
product
candidates
advanced
program
using
company
tv
technology
etv
ids
hunter
syndrome
mps
ii
currently
phase
study
denali
therapeutics
denali
therapeutics
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
neurodegenerative
diseases
denali
pursues
new
treatments
rigorously
assessing
genetically
validated
targets
engineering
delivery
across
bbb
guiding
development
biomarkers
demonstrate
target
pathway
engagement
denali
based
south
san
francisco
additional
information
please
visit
cautionary
note
regarding
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
expressed
implied
press
release
include
limited
plans
timelines
expectations
related
denali
tv
technology
platform
tv
programs
ability
effectively
deliver
large
therapeutic
molecules
antibodies
enzymes
proteins
oligonucleotides
across
bbb
intravenous
administration
expectations
regarding
commencement
clinical
trials
plans
announce
data
interim
analysis
safety
biomarker
data
csf
gag
reduction
year
end
expectations
regarding
ongoing
clinical
trials
statements
denali
chief
executive
officer
chief
medical
officer
actual
results
subject
risks
uncertainties
may
differ
materially
indicated
statements
result
risks
uncertainties
including
limited
risks
denali
business
operations
caused
directly
indirectly
evolving
pandemic
denali
early
stages
clinical
drug
development
denali
partners
ability
complete
development
approved
commercialization
product
candidates
denali
partners
ability
enroll
patients
clinical
trials
denali
reliance
third
parties
manufacture
supply
product
candidates
clinical
trials
denali
dependence
successful
development
bbb
platform
technology
bbb
product
candidates
including
whether
platform
technology
effectively
delivers
therapeutic
molecules
across
bbb
increased
exposure
distribution
brain
increases
therapeutic
efficacy
administration
leads
improvements
lysosomal
neurodegeneration
biomarkers
including
neurocognitive
outcomes
denali
partners
ability
conduct
complete
clinical
trials
expected
timelines
uncertainty
product
candidates
receive
regulatory
approval
necessary
commercialized
denali
ability
continue
create
pipeline
product
candidates
develop
commercially
successful
products
developments
relating
denali
competitors
industry
including
competing
product
candidates
therapies
denali
ability
obtain
maintain
protect
intellectual
property
rights
related
product
candidates
implementation
denali
strategic
plans
business
product
candidates
bbb
platform
technology
denali
ability
obtain
additional
capital
finance
operations
needed
denali
ability
accurately
forecast
future
financial
results
current
environment
general
economic
market
conditions
risks
uncertainties
including
described
denali
recent
annual
report
form
recent
quarterly
report
form
denali
future
reports
filed
sec
statements
press
release
based
information
available
denali
date
hereof
denali
disclaims
obligation
update
statements
except
required
law
reference
bhalla
et
al
characterization
fluid
biomarkers
reveals
lysosome
dysfunction
neurodegeneration
neuronopathic
mps
ii
patients
int
j
mol
sci
jul
doi
investor
relations
contact
laura
hansen
vice
president
investor
relations
hansen
media
contacts
lizzie
hyland
lhyland
morgan
warners
mwarners
